nach oben

Erschienen in:

26.01.2017 | Original Article

Human cytomegalovirus (HCMV) UL44 and UL57 specific antibody responses in anti-HCMV-positive patients with systemic sclerosis

verfasst von: Emmanouela Marou, Christos Liaskos, Theodora Simopoulou, Georgios Efthymiou, Efthymios Dardiotis, Christina Katsiari, Thomas Scheper, Wolfgang Meyer, Georgios Hadjigeorgiou, Dimitrios P. Bogdanos, Lazaros I. Sakkas

Erschienen in: Clinical Rheumatology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The role of human cytomegalovirus (HCMV) has been postulated as a trigger of systemic sclerosis (SSc). The aim of the study was to assess the prevalence of antibodies against HCMV UL44 and UL57 antigens not tested in the past. Sixty SSc patients, 40 multiple sclerosis and 17 normal controls (NCs), all anti-HCMV positive, were tested by immunoblotting. Reactivity to HCMV antigens, expressed as arbitrary units (AUs), was assessed for correlation with clinical and immunological parameters, including types of SSc-related autoantibodies. Anti-UL44 and anti-UL57 HCMV antibodies were present in 3/60 (5%) and 58/60 (96.7%) SSc patients, respectively (p < 0.001). Anti-UL57 antibodies were present in 35/40 (87.5%) MS patients and 16/17 (94.1%) NCs (SSc vs MS, MS vs NC, p = ns). Strong (50-75 AU) and very strong (75–100 AU) anti-UL57 immunoreactivity was found in 24 (41.4%) and 22 (37.9%) SSc patients, respectively (p = ns). Dilution experiments showed anti-UL57 antibody persistence in up to 1/5000. Overall, there was no difference in the frequency or the magnitude of anti-UL57 immunoreactivity between diffuse cutaneous systemic sclerosis and limited cutaneous systemic sclerosis patients (96.67 vs 96.67%; 65.45 ± 20.19 vs 64.31 ± 21.11 AU, p > 0.05) but strong anti-UL57 reactivity were more frequent in SSc compared to NCs (p = 0.007). Anti-UL57 reactivity was not inhibited by SSc-specific autoantigens. Anti-UL57 seropositivity did not correlate with demographic, clinical or immunological features of SSc. Anti-HCMV UL57 antibodies are universally present in anti-HCMV-positive patients with SSc, while those against UL44 are rarely seen. Because anti-UL57 lack disease specificity and are not involved in cross-reactive responses, their immunopathogenetic potential is to be questioned.

Sakkas LI, Chikanza IC, Platsoucas CD (2012) Systemic sclerosis: from pathogenesis towards targeted immunotherapies. Curr Rheumatol Rev 8:45–55CrossRef

Chora I, Guiducci S, Manetti M, Romano E, Mazzotta C, Bellando-Randone S, Ibba-Manneschi L, Matucci-Cerinic M, Soares R (2015) Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev 14(4):314–322. doi:10.1016/j.autrev.2014.12.001 CrossRefPubMed

Ho YY, Lagares D, Tager AM, Kapoor M (2014) Fibrosis—a lethal component of systemic sclerosis. Nat Rev Rheumatol 10(7):390–402. doi:10.1038/nrrheum.2014.53 CrossRefPubMed

Sakkas LI, Chikanza IC, Platsoucas CD (2006) Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2(12):679–685. doi:10.1038/ncprheum0346 CrossRefPubMed

Domsic RT (2014) Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol 26(6):646–652. doi:10.1097/BOR.0000000000000113 CrossRefPubMedPubMedCentral

Kayser C, Fritzler MJ (2015) Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol 6:167. doi:10.3389/fimmu.2015.00167 CrossRefPubMedPubMedCentral

Sakkas LI, Bogdanos DP (2016) Systemic sclerosis: new evidence re-enforces the role of B cells. Autoimmun Rev 15(2):155–161. doi:10.1016/j.autrev.2015.10.005 CrossRefPubMed

Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE (2015) Pathogenesis of systemic sclerosis. Front Immunol 6:272. doi:10.3389/fimmu.2015.00272 CrossRefPubMedPubMedCentral

Riccieri V, Parisi G, Spadaro A, Scrivo R, Barone F, Moretti T, Bernardini G, Strom R, Taccari E, Valesini G (2005) Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J Rheumatol 32(2):283–286PubMed

10.

Murdaca G, Contatore M, Gulli R, Mandich P, Puppo F (2016) Genetic factors and systemic sclerosis. Autoimmun Rev 15(5):427–432. doi:10.1016/j.autrev.2016.01.016 CrossRefPubMed

11.

Halenius A, Hengel H (2014) Human cytomegalovirus and autoimmune disease. Biomed Res Int 2014:472978. doi:10.1155/2014/472978 CrossRefPubMedPubMedCentral

12.

Marie I, Gehanno JF (2015) Environmental risk factors of systemic sclerosis. Semin Immunopathol. doi:10.1007/s00281-015-0507-3 PubMed

13.

Bogdanos DP, Smyk DS, Rigopoulou EI, Sakkas LI, Shoenfeld Y (2015) Infectomics and autoinfectomics: a tool to study infectious-induced autoimmunity. Lupus 24(4–5):364–373. doi:10.1177/0961203314559088 CrossRefPubMed

14.

Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Sakkas L, Pouria S, Shoenfeld Y (2013) Tracing environmental markers of autoimmunity: introducing the infectome. Immunol Res 56(2–3):220–240. doi:10.1007/s12026-013-8399-6 CrossRefPubMed

15.

Elisa T, Antonio P, Giuseppe P, Alessandro B, Giuseppe A, Federico C, Marzia D, Ruggero B, Giacomo M, Andrea O, Daniela R, Mariaelisa R, Claudio L (2015) Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis. J Immunol Res 2015:147616. doi:10.1155/2015/147616 CrossRefPubMedPubMedCentral

16.

Magro CM, Crowson AN, Ferri C (2007) Cytomegalovirus-associated cutaneous vasculopathy and scleroderma sans inclusion body change. Hum Pathol 38(1):42–49. doi:10.1016/j.humpath.2006.06.002 CrossRefPubMed

17.

Pandey JP (2004) Immunoglobulin GM genes and IgG antibodies to cytomegalovirus in patients with systemic sclerosis. Clin Exp Rheumatol 22(3 Suppl 33):S35–S37PubMed

18.

Pandey JP, LeRoy EC (1998) Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 41(1):10–15. doi:10.1002/1529-0131(199801)41:1<10::AID-ART2>3.0.CO;2-P CrossRefPubMed

19.

Moinzadeh P, Khan K, Ong VH, Denton CP (2012) Sustained improvement of diffuse systemic sclerosis following human cytomegalovirus infection offers insight into pathogenesis and therapy. Rheumatology (Oxford) 51(12):2296–2298. doi:10.1093/rheumatology/kes137 CrossRef

20.

Vaughan JH, Shaw PX, Nguyen MD, Medsger TA Jr, Wright TM, Metcalf JS, Leroy EC (2000) Evidence of activation of 2 herpesviruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skins. J Rheumatol 27(3):821–823PubMed

21.

Dolcino M, Puccetti A, Barbieri A, Bason C, Tinazzi E, Ottria A, Patuzzo G, Martinelli N, Lunardi C (2015) Infections and autoimmunity: role of human cytomegalovirus in autoimmune endothelial cell damage. Lupus 24(4–5):419–432. doi:10.1177/0961203314558677 CrossRefPubMed

22.

Muryoi T, Kasturi KN, Kafina MJ, Cram DS, Harrison LC, Sasaki T, Bona CA (1992) Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 175(4):1103–1109CrossRefPubMed

23.

Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, Maya R, Shoenfeld Y (2009) The role of infections in the immunopathogensis of systemic sclerosis—evidence from serological studies. Ann N Y Acad Sci 1173:627–632. doi:10.1111/j.1749-6632.2009.04808.x CrossRefPubMed

24.

Pastano R, Dell’Agnola C, Bason C, Gigli F, Rabascio C, Puccetti A, Tinazzi E, Cetto G, Peccatori F, Martinelli G, Lunardi C (2012) Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease. Int Immunol 24(9):583–591. doi:10.1093/intimm/dxs061 CrossRefPubMed

25.

Namboodiri AM, Rocca KM, Pandey JP (2004) IgG antibodies to human cytomegalovirus late protein UL94 in patients with systemic sclerosis. Autoimmunity 37(3):241–244CrossRefPubMed

26.

Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R, Puccetti A (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6(10):1183–1186. doi:10.1038/80533 CrossRefPubMed

27.

Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, Tamassia N, Beri R, Corrocher R, Puccetti A (2006) Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 3(1):e2. doi:10.1371/journal.pmed.0030002 CrossRefPubMed

28.

Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, Tamassia N, Tinazzi E, Beri R, Corrocher R, Puccetti A (2007) Endothelial cells’ activation and apoptosis induced by a subset of antibodies against human cytomegalovirus: relevance to the pathogenesis of atherosclerosis. PLoS One 2(5):e473. doi:10.1371/journal.pone.0000473 CrossRefPubMedPubMedCentral

29.

Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT (2002) IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome. Vivo 16(3):153–159

30.

Efthymiou G, Dardiotis E, Liaskos C, Marou E, Tsimourtou V, Hadjigeorgiou GM, Scheper T, Meyer W, Daponte A, Sakkas LI, Bogdanos DP (2016) Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)relevance to disease pathogenesis. J Neuroimmunol 298:19–23CrossRefPubMed

31.

Mavropoulos A, Simopoulou T, Varna A, Liaskos C, Katsiari CG, Bogdanos DP, Sakkas LI (2016) Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis. Arthritis Rheumatol 68(2):494–504. doi:10.1002/art.39437 CrossRefPubMed

32.

Neidhart M, Kuchen S, Distler O, Bruhlmann P, Michel BA, Gay RE, Gay S (1999) Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 42(2):389–392. doi:10.1002/1529-0131(199902)42:2<389::AID-ANR23>3.0.CO;2-P CrossRefPubMed

33.

Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y (2007) Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 1108:567–577CrossRefPubMed

34.

Vanheusden M, Stinissen P, t Hart BA, Hellings N (2015) Cytomegalovirus: a culprit or protector in multiple sclerosis? Trends Mol Med 21(1):16–23. doi:10.1016/j.molmed.2014.11.002 CrossRefPubMed

35.

Riccieri V, Alessandri C, Germano V, Guiducci S, Rogai V, Colasanti T, Delunardo F, Margutti P, Ortona E, Cerinic MM, Valesini G (2010) Nedd5, a novel autoantigen in systemic sclerosis: is it a marker of more severe disease? Ann Rheum Dis 69(1):314–315. doi:10.1136/ard.2009.111302 CrossRefPubMed

36.

Margutti P, Sorice M, Conti F, Delunardo F, Racaniello M, Alessandri C, Siracusano A, Rigano R, Profumo E, Valesini G, Ortona E (2005) Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations. Arthritis Res Ther 7(4):R896–R903. doi:10.1186/ar1759 CrossRefPubMedPubMedCentral

37.

Riemekasten G, Cabral-Marques O (2016) Antibodies against angiotensin II type 1 receptor (AT1R) and endothelin receptor type A (ETAR) in systemic sclerosis (SSc)-response. Autoimmun Rev. doi:10.1016/j.autrev.2016.04.004

Titel: Human cytomegalovirus (HCMV) UL44 and UL57 specific antibody responses in anti-HCMV-positive patients with systemic sclerosis
verfasst von: Emmanouela Marou
Christos Liaskos
Theodora Simopoulou
Georgios Efthymiou
Efthymios Dardiotis
Christina Katsiari
Thomas Scheper
Wolfgang Meyer
Georgios Hadjigeorgiou
Dimitrios P. Bogdanos
Lazaros I. Sakkas
Publikationsdatum: 26.01.2017
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 4/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3553-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Association of human leukocyte A, B, and DR antigens in Colombian patients with diagnosis of spondyloarthritis

Ten-year progression of coronary artery, carotid artery, and aortic calcification in patients with rheumatoid arthritis

Mannose-binding lectin (MBL) codon 54 (rs1800450) polymorphism predisposes towards medium vessel vasculitis in patients with systemic lupus erythematosus

Muckle-Wells syndrome in Chinese patients: a single center case series

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA)